Metabolic syndrome in patients with schizophrenia and antipsychotic treatment

Eva Aguilar, Ramón Coronas, Assumpta Caixàs

Research output: Contribution to journalReview articleResearchpeer-review

12 Citations (Scopus)


Patients with schizophrenia have a shorter life expectancy and their risk of dying from a cardiovascular disease is higher than the general population. Both facts have been attributed to the raised presence of metabolic syndrome. There is a big amount of scientific publications that deals with the relationship between schizophrenia, antipsychotic treatment, and the development of metabolic syndrome. There is also information about recommendations and clinical guides to achieve an adequate prevention, screening, and treatment of the disease. The aim of this review is to update the current information about this issue and to understand related etiologic factors, differences between antipsychotic drugs, and the current recommendations for patient's care. © 2011 Elsevier Espana, S.L. Todos los derechos reservados.
Original languageEnglish
Pages (from-to)542-546
Number of pages4
JournalMedicina Clinica
Issue number12
Publication statusPublished - 17 Nov 2012


  • Antipsychotic
  • Cardiovascular risk
  • Metabolic syndrome
  • Schizophrenia


Dive into the research topics of 'Metabolic syndrome in patients with schizophrenia and antipsychotic treatment'. Together they form a unique fingerprint.

Cite this